Why Total Cost of Ownership Is the Only Medical Device Price That Matters

Ask any hospital buyer: the real cost of a device shows up after the invoice. I'm the purchasing administrator for a 300-bed regional hospital. I manage roughly $2.2 million in annual cardiac and critical care spending across 9 vendors, and I report to both operations and finance. After five years of this, I have a strong opinion: buying an ECG machine, an MRI machine, or a hemodynamic monitoring platform by sticker price alone is how you end up in the CFO's office with bad news.

If you compare only the unit price before you compare the five-year cost, you are not saving money—you're just deferring it.

That's not a slogan. It's the lesson I learned when I took over procurement in 2020.

The $8,000 Lesson: Sticker Shock vs. Real Cost

One of the first purchases I managed involved bedside monitors. We needed to replace part of our telemetry fleet, and the initial quotes fell into two camps: one around $40,000 per unit, another around $48,000. I pushed the cheaper option because, well, that's what procurement does—save money.

Then I started adding up the extras. Installation was separate. Training was separate. The service contract was annual. The more expensive quote, it turned out, included a three-year service plan, staff training, and integration with our existing EMR. When I compared the two quotes side by side—same clinical needs, completely different cost structures—I finally understood why total cost of ownership matters. The 'cheap' system was roughly $9,000 more in the first 18 months.

From the outside, it looks like the lower quote means the vendor is more efficient. What you don't see is which costs are being deferred to the purchase order after the purchase order. Shipping, setup, training, calibration, software licenses, integration, downtime—someone pays for those. If you haven't asked who, you're the one.

An ECG Machine and an MRI Machine Are Different Devices. Same Mistake.

I use ECG machines and MRI machines as the extreme ends of the equipment spectrum. One is a cart you can move down a hallway. The other consumes an entire room and has a magnet the size of a small car. But the purchasing trap is identical.

An ECG machine might have a low acquisition price, yet the real cost lives in the consumables, the yearly ECG interpretation software subscription, the battery failures after two years, and the service visits that seem to happen right after the warranty expires. An MRI machine has higher fixed costs and more moving parts—literally—so the TCO difference gets even larger. The vendor's support structure, uptime guarantees, and upgrade path matter more than the number on the first page of the quote.

I don't make those decisions alone. The clinical team tells me what they need. But when I present options, I now include a simple TCO model that splits cost into three buckets:

• Acquisition cost: hardware, software, installation, first-year training.
• Operating cost: service plans, consumables, calibration, power usage, staff time.
• Risk cost: downtime, rework, safety events, compliance gaps, replacement timeline.

As of January 2025, when I updated our capital equipment scorecard, I made those three buckets mandatory. We don't move forward until every quote is mapped onto the same structure.

Point of Care Testing: A Perfect Example of Hidden Cost

Let's talk about point of care testing, or POCT—because a lot of people ask 'what is point of care testing' and then assume it's simply a faster lab test. It is, but the TCO effect is much deeper.

Point of care testing means running diagnostic tests right at the patient's bedside or in the ED, instead of sending samples to a central lab. For a septic patient in the ICU, a 20-minute turnaround can change a treatment decision. That clinical value is obvious. But the procurement question is whether the POCT device's consumable pricing, operator training, and quality controls are priced into the rollout. In my experience, they often are not. You can get a low-cost POCT analyzer and then pay a fortune for each test cartridge, or underestimate the training time for new nursing shifts.

When we built our POCT business case in 2024, we didn't just compare the analyzer prices. We included the cost per test, the expected number of tests, the training materials, the EMR integration, and the time nurses spent troubleshooting errors. The least expensive analyzer had the highest five-year TCO. That's the exact scenario I now warn every new buyer about: the machine is cheap because the real margin is in the consumables.

Why Edwards Lifesciences Recent News and Website Matter to a Hospital Buyer

I also watch vendor roadmaps before I commit to a platform. That's why I keep an eye on Edwards Lifesciences recent news and check the Edwards Lifesciences website (edwards.com) when I evaluate critical care monitoring and structural heart technology. Not because every product will fit our hospital, but because the company's investment direction tells me how long a platform might stay relevant.

For instance, if a hemodynamic monitoring system is described as part of a broader platform with software updates and expanded data integration, I can assume a longer useful life than a standalone product that hasn't changed in years. Recent Edwards Lifesciences announcements about monitoring and structural heart innovation matter to a buyer like me, because they signal whether my five-year investment will become obsolete before the depreciation schedule catches up.

You can find the same information from any serious medical device manufacturer. The point isn't to brand-praise. The point is that vendor viability and roadmap investment are part of TCO. A device from a company that stops investing in its software can cost you more in replacements, interoperability workarounds, and lost clinical efficiency than any purchase-price savings.

When I check an Edwards Lifesciences website page for a monitoring platform, I'm not comparing, 'Who has the newest feature?' I'm asking, 'Can this system grow with us, and what does the total cost look like over the next five years?' That's the mindset that has to replace 'which quote is lower?'

But What About This Year's Budget? (The Objection I Always Hear)

I know what some finance teams will say: 'We have to fit the purchase into this year's capital budget, not a five-year fantasy.' I get that. I live it. But you can use TCO without creating a multi-year budget model.

Take the three buckets above and assign them a simple score. Acquisition cost is the invoice. Operating cost is the annual maintenance and consumable estimate. Risk cost is the probability-weighted cost of downtime and rework. You don't need perfect data. You need to stop pretending the first bucket is the total.

Yes, the higher upfront option can hurt this year's budget. But the actual total net present value is often lower. When I explain it that way, finance doesn't fight me. They fight me when I come back six months later asking for $60,000 in unforeseen installation and training fees from the 'cheaper' vendor.

Dodged a bullet on exactly that in 2023. I was one signature away from approving a low-price defibrillator contract that didn't include any lead integration or staff competency checks. The clinical engineering team flagged it, and we renegotiated with a total-cost contract that was $12,000 more upfront but about $31,000 less over three years. So glad I checked—almost signed away not just money, but also a lot of future stress.

And then there's the other part of satisfaction. There's something genuinely reassuring about an invoice that matches the approved quote. No surprise freight. No last-minute 'that's not included' line items. After years of chasing down unexplained fees, that's the real luxury.

Bottom Line: Buy the Outcome, Not the Sticker

I'm not romanticizing procurement. I still get pressure to hit a lower unit price, and sometimes that pressure wins. But every time it wins, the total cost turns out to be higher. That's not an opinion anymore; it's a pattern I've watched repeat across ECG machines, MRI machines, point of care testing systems, and hemodynamic monitoring platforms.

So here's my view: the correct procurement question is not, 'Who has the cheapest device?' It's, 'What does the device cost when you account for everything it touches—the people, the software, the service, the risk, and the time it stays relevant?'

That is the total cost of ownership. And it's the only number that should ever be called the price.